首页> 外国专利> PATIENT SELECTION METHOD FOR ULTRASOUND HEMIABLATION OF LOCALIZED PROSTATE CANCER

PATIENT SELECTION METHOD FOR ULTRASOUND HEMIABLATION OF LOCALIZED PROSTATE CANCER

机译:局部前列腺癌超声半透明化的患者选择方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to oncourology, and can be used for the selection of patients for ultrasound hemiablation of localized prostate cancer. Perineal polyfocal biopsy of the prostate gland, multiparameter magnetic resonance imaging are performed. Additionally, a study of the initial level of prostate-specific antigen is performed. Perineal biopsy of the prostate gland is performed with a sampling of at least 24 biopsy samples. Tumor immunohistochemical profile is determined. Ultrasonic hemiablation is considered as justified if an initial level of prostate-specific antigen of no more than 10 ng/ml, the presence of unifocal, unilateral lesions of the prostate gland according to the data of multiparametric magnetic resonance imaging and histological examination data: the Gleason index is not more than 6, the absence of perineural invasion, the percentage of lesions within the biopsy is no more than 50 %, Grade 1–2, and with absolute values of the apoptosis marker p53 – 50 %, and proliferative activity of Ki-67 – 70 %.;EFFECT: method provides the possibility and efficiency of performing ultrasound hemiablation of localized forms of prostate cancer by creating selection criteria for patients with this pathology.;1 cl, 1 ex
机译:技术领域本发明涉及医学,即肿瘤学,并且可以用于选择用于局部前列腺癌的超声半消融的患者。前列腺的会阴多焦点活检,进行多参数磁共振成像。另外,进行了前列腺特异性抗原的初始水平的研究。前列腺腺的会阴活检是对至少24个活检样本进行采样。确定了肿瘤免疫组织化学特征。根据多参数磁共振成像和组织学检查数据,如果前列腺特异性抗原的初始水平不超过10ng / ml,存在前列腺的单灶,单侧病变,则超声半消融被认为是合理的。格里森指数不大于6,不存在神经周围浸润,活检中病变的百分比不超过50%,1-2级,并且具有凋亡标记p53-50%的绝对值,且其增殖活性为Ki-67 – 70%。;效果:该方法通过为具有这种病理学的患者制定选择标准,提供了对局部形式的前列腺癌进行超声半消融的可能性和效率。1cl,1 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号